Adults with Primary Hypercholesterolemia or HeFH
The efficacy of LEQVIO was investigated in three randomized, double-blind, placebo-controlled trials that enrolled 3,660 adults with HeFH, clinical ASCVD, or increased risk for ASCVD, who were taking maximally tolerated statin therapy and who required additional LDL-C lowering. Demographics and baseline disease characteristics were balanced between the treatment arms in all trials.
Adults with Primary Hypercholesterolemia
Trial 1 (ORION-10, NCT03399370) was a multicenter, double-blind, randomized, placebo-controlled 18-month trial in which 1,561 adults with ASCVD were randomized 1:1 to receive subcutaneous injections of either LEQVIO 284 mg (n = 781) or placebo (n = 780) on Day 1, Day 90, Day 270, and at Day 450. Patients were taking a maximally tolerated dose of statin with or without other lipid modifying therapy and required additional LDL-C reduction. Patients were stratified by current use of statins or other lipid-modifying therapies. Patients taking PCSK9 inhibitors were excluded from the trial.
The mean age at baseline was 66 years (range: 35 to 90 years), 60% were ≥65 years old, 31% were female, 86% were White, 13% were Black or African American, 1% were Asian, and 14% identified as Hispanic or Latino ethnicity. Forty-five percent (45%) of patients had diabetes at baseline. The mean baseline LDL-C was 105 mg/dL. At the time of randomization, 89% of patients were receiving statin therapy and 69% were receiving high-intensity statin therapy.
The primary efficacy outcome measure in Trial 1 was the percent change from baseline to Day 510 in LDL-C. The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to Day 510 was -52% (95% CI: -56%, -49%; p < 0.0001). For additional results, see Table 2 and Figure 1.
Table 2: Changes in Lipid Parameters in Adults with Hypercholesterolemia and ASCVD on Maximally Tolerated Statin Therapy (Mean % Change from Baseline to Day 510 in Trial 1) | Treatment Group | LDL-C | Total Cholesterol | Non-HDL-C | ApoB |
|---|
ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol
a11.5% of subjects on LEQVIO and 14.6% of subjects on placebo had missing LDL-C data at primary endpoint (Day 510). Missing data were imputed using a modified control-based multiple imputation to account for treatment adherence. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with fixed effect for treatment group and baseline LDL-C as a covariate. Other endpoints were analyzed using a mixed-effect model for repeated measure (MMRM) with fixed effects for treatment group, visit, interaction between treatment and visit, and baseline value. Missing data were imputed using a control-based pattern-mixture model approach. |
| Day 510 (mean percentage change from baseline)a |
| Placebo (n = 780) | 1 | 0 | 0 | -2 |
| LEQVIO (n = 781) | -51 | -34 | -47 | -45 |
| Difference from placebo (LS Mean) (95% CI) | -52 (-56, -49) | -33 (-35, -31) | -47 (-50, -44) | -43 (-46, -41) |
Figure 1: Mean Percent Change from Baseline in LDL-C Over 18 Months in Adults with Hypercholesterolemia and ASCVD on Maximally Tolerated Statin Therapy (Trial 1)
Figure 1: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hypercholesterolemia And Ascvd On Maximally Tolerated Statin Therapy (trial 1) (Leqvio 02)
Trial 2 (ORION-11, NCT03400800) was a multicenter, double-blind, randomized, placebo-controlled 18-month trial in which 1,617 adults with ASCVD or increased risk for ASCVD were randomized 1:1 to receive subcutaneous injections of either LEQVIO 284 mg (n = 810) or placebo (n = 807) on Day 1, Day 90, Day 270, and at Day 450. Patients were taking a maximally tolerated dose of statin with or without other lipid modifying therapy and required additional LDL-C reduction. Patients were stratified by country and by current use of statins or other lipid-modifying therapies. Patients taking PCSK9 inhibitors were excluded from the trial.
The mean age at baseline was 65 years (range: 20 to 88 years), 55% were ≥65 years old, 28% were female, 98% were White, 1% were Black or African American, and <1% were Asian; <1% identified as Hispanic or Latino ethnicity. Thirty-five percent (35%) of patients had diabetes at baseline. The mean baseline LDL-C was 105 mg/dL. At the time of randomization, 95% of patients were receiving statin therapy and 78% were receiving high-intensity statin therapy.
The primary efficacy outcome measure in Trial 2 was the percent change from baseline to Day 510 in LDL-C. The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to Day 510 was -50% (95% CI: -53%, -47%; p < 0.0001). For additional results, see Table 3 and Figure 2.
Table 3: Changes in Lipid Parameters in Adults with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD on Maximally Tolerated Statin Therapy (Mean % Change from Baseline to Day 510 in Trial 2)| Treatment Group | LDL-C | Total Cholesterol | Non-HDL-C | ApoB |
|---|
ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol
a10.6% of subjects on LEQVIO and 8.4% of subjects on placebo had missing LDL-C data at primary endpoint (Day 510). Missing data were imputed using a modified control-based multiple imputation to account for treatment adherence. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with fixed effect for treatment group and baseline LDL-C as a covariate. Other endpoints were analyzed using a mixed-effect model for repeated measure (MMRM) with fixed effects for treatment group, visit, interaction between treatment and visit, and baseline value. Missing data were imputed using a control-based pattern-mixture model approach. |
| Day 510 (mean percentage change from baseline)a |
| Placebo (n = 807) | 4 | 2 | 2 | 1 |
| LEQVIO (n = 810) | -46 | -28 | -41 | -38 |
| Difference from placebo (LS Mean) (95% CI) | -50 (-53, -47) | -30 (-32, -28) | -43 (-46, -41) | -39 (-41, -37) |
Figure 2: Mean Percent Change from Baseline in LDL-C Over 18 Months in Adults with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD on Maximally Tolerated Statin Therapy (Trial 2)
Figure 2: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hypercholesterolemia And Ascvd Or Increased Risk For Ascvd On Maximally Tolerated Statin Therapy (trial 2) (Leqvio 03)
In a pooled analysis of Trial 1 and Trial 2, the observed treatment effect was similar across predefined subgroups, such as sex, age, race, disease characteristics, geographic regions, presence of diabetes, body mass index, baseline LDL-C levels, and intensity of statin treatment.
Adults with HeFH
Trial 3 (ORION-9, NCT03397121) was a multicenter, double-blind, randomized, placebo-controlled 18-month trial in which 482 adults with HeFH were randomized 1:1 to receive subcutaneous injections of either LEQVIO 284 mg (n = 242) or placebo (n = 240) on Day 1, Day 90, Day 270, and at Day 450. Patients with HeFH were taking a maximally tolerated dose of statin with or without other lipid modifying therapy and required additional LDL-C reduction. The diagnosis of HeFH was made either by genotyping or clinical criteria using either the Simon Broome or WHO/Dutch Lipid Network criteria. Patients were stratified by country and by current use of statins or other lipid-modifying therapies. Patients taking PCSK9 inhibitors were excluded from the trial.
The mean age at baseline was 55 years (range: 21 to 80 years), 22% were ≥65 years old, 53% were female, 94% were White, 3% were Black or African American, and 3% were Asian; and 3% identified as Hispanic or Latino ethnicity. Ten percent (10%) of patients had diabetes at baseline. The mean baseline LDL-C was 153 mg/dL. At the time of randomization, 90% of patients were receiving statin therapy and 74% were receiving high-intensity statin therapy. Fifty-two percent (52%) of patients were treated with ezetimibe. The most commonly administered statins were atorvastatin and rosuvastatin.
The primary efficacy outcome measure in Trial 3 was the percent change from baseline to Day 510 in LDL-C. The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to Day 510 was -48% (95% CI: -54%, -42%; p < 0.0001). For additional results, see Table 4 and Figure 3.
Table 4: Changes in Lipid Parameters in Adults with HeFH on Maximally Tolerated Statin Therapy (Mean % Change from Baseline to Day 510 in Trial 3)| Treatment Group | LDL-C | Total Cholesterol | Non-HDL-C | ApoB |
|---|
ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol
a4.5% of subjects on LEQVIO and 4.6% of subjects on placebo had missing LDL-C data at primary endpoint (Day 510). Missing data were imputed using a modified control-based multiple imputation to account for treatment adherence. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with fixed effect for treatment group and baseline LDL-C as a covariate. Other endpoints were analyzed using mixed-effect model for repeated measure (MMRM) with fixed effects for treatment group, visit, interaction between treatment and visit, and baseline value as a covariate. Missing data were imputed using a control-based pattern-mixture model approach. |
| Day 510 (mean percentage change from baseline)a |
| Placebo (n = 240) | 8 | 7 | 7 | 3 |
| LEQVIO (n = 242) | -40 | -25 | -35 | -33 |
| Difference from placebo (LS Mean) (95% CI) | -48 (-54, -42) | -32 (-36, -28) | -42 (-47, -37) | -36 (-40, -32) |
Figure 3: Mean Percent Change from Baseline in LDL-C Over 18 Months in Adults with HeFH on Maximally Tolerated Statin Therapy (Trial 3)
Figure 3: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hefh On Maximally Tolerated Statin Therapy (trial 3) (Leqvio 04)
Pediatric Patients with HeFH
Trial 4 (ORION-16, NCT04652726) was a 12-month randomized, double-blind, placebo-controlled trial in 141 pediatric patients aged 12 years and older with HeFH and elevated LDL-C. Patients were receiving maximally tolerated statin therapy with or without additional LDL-C-lowering therapies. The diagnosis of HeFH was made either by genetic testing or clinical criteria. Patients were randomized in a 2:1 ratio to receive subcutaneous injections of either LEQVIO 284 mg (n = 93) or placebo (n = 48) on Day 1, Day 90, and Day 270.
The mean age at baseline was 15 years (range: 12 to 17 years), 53% were female, 91% were White, 4% were Black or African American, 3% were Asian, and 3% were other races; 9% identified as Hispanic or Latino ethnicity. The mean LDL-C at baseline was 183 mg/dL; 93% of patients were taking statins and 23% were on ezetimibe.
The primary efficacy outcome measure in Trial 4 was the percent change from baseline to Day 330 in LDL-C. The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to Day 330 was -29% (95% CI: −36%, −21%; p < 0.0001). For additional results, see Table 5 and Figure 4.
Table 5: Changes in Lipid Parameters in Pediatric Patients aged 12 Years and Older with HeFH (Mean % Change from Baseline to Day 330 in Trial 4)| Treatment Group | LDL-C | ApoB | Non-HDL-C | Total Cholesterol |
|---|
ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol
a3.2% of subjects on LEQVIO and 0% of subjects on placebo had missing LDL-C data at primary endpoint (Day 330). Missing data were imputed using a modified control-based multiple imputation to account for treatment adherence. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with fixed effects for treatment group and baseline age group, and baseline LDL-C as a covariate. Other endpoints were analyzed using same approach. |
| Day 330 (mean percentage change from baseline)a |
| Placebo (n = 48) | 1 | 4 | 2 | 0 |
| LEQVIO (n = 93) | -27 | -21 | -25 | -19 |
| Difference from placebo (LS Mean) (95% CI) | -29 (-36, -21) | -26 (-32, -20) | -27 (-34, -20) | -19 (-25, -14) |
Figure 4: Mean Percent Change from Baseline in LDL-C Over 12 Months in Pediatric Patients aged 12 Years and Older with HeFH (Trial 4)
Figure 4: Mean Percent Change From Baseline In Ldl-c Over 12 Months In Pediatric Patients Aged 12 Years And Older With Hefh (trial 4) (Leqvio 11)
Pediatric Patients with HoFH
Trial 5 (ORION-13, NCT04659863) was a 12-month randomized, double-blind, placebo-controlled trial in 13 pediatric patients aged 12 years and older with HoFH and elevated LDL-C. All patients were taking LDL-C-lowering therapies. Patients with a null (negative) variant in both low-density lipoprotein receptor (LDLR) alleles, who were considered unlikely to benefit from a reduction in PCSK9, were excluded. The diagnosis of HoFH was made by genetic testing. Patients were randomized in a 2:1 ratio to receive subcutaneous injections of either LEQVIO 284 mg (n = 9) or placebo (n = 4) on Day 1, Day 90, and Day 270.
The mean age at baseline was 15 years (range: 12 to 17 years), 69% were female, 85% were White, and 15% were Asian; 8% identified as Hispanic or Latino ethnicity. The mean LDL-C at baseline was 272 mg/dL; all patients were taking statins and 85% were on ezetimibe.
The primary efficacy outcome measure in Trial 5 was the percent change from baseline to Day 330 in LDL-C. The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to Day 330 was -33% (95% CI: −80%, 13%). For additional results, see Table 6 and Figure 5.
Table 6: Changes in Lipid Parameters in Pediatric Patients aged 12 Years and Older with HoFH (Mean % Change from Baseline to Day 330 in Trial 5)| Treatment Group | LDL-C | ApoB | Non-HDL-C | Total Cholesterol |
|---|
ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol
The trial was designed as a descriptive trial and was not powered to test any hypothesis.
aNo subject in either LEQVIO or placebo had missing LDL-C data at primary endpoint (Day 330). No statistical model was performed. The mean and 95% CI of the difference from placebo were calculated based on a t-distribution for the percent change from baseline in LDL-C and other endpoints. |
| Day 330 (mean percentage change from baseline)a |
| Placebo (n = 4) | 12 | 5 | 9 | 9 |
| LEQVIO (n = 9) | -22 | -19 | -23 | -19 |
| Difference from placebo (Mean) (95% CI) | -33 (-80, 13) | -23 (-50, 4) | -33 (-87, 22) | -28 (-75, 19) |
Figure 5: Mean Percent Change from Baseline in LDL-C Over 12 Months in Pediatric Patients aged 12 Years and Older with HoFH (Trial 5)
Figure 5: Mean Percent Change From Baseline In Ldl-c Over 12 Months In Pediatric Patients Aged 12 Years And Older With Hofh (trial 5) (Leqvio 12)